Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Petronella O. Witteveen"'
Autor:
Maartje M. W. Luijten, Willem Jan van Weelden, Roy I. Lalisang, Johan Bulten, Kristina Lindemann, Heleen J. van Beekhuizen, Hans Trum, Dorry Boll, Henrica M. J. Werner, Luc R. C. W. van Lonkhuijzen, Refika Yigit, Camilla Krakstad, Petronella O. Witteveen, Khadra Galaal, Alexandra A. van Ginkel, Eliana Bignotti, Vit Weinberger, Sanne Sweegers, Ane Gerda Z. Eriksson, Diederick M. Keizer, Anja van de Stolpe, Andrea Romano, Johanna M. A. Pijnenborg, European Network for Individualized Treatment in Endometrial Cancer
Publikováno v:
Cancers, Vol 16, Iss 11, p 2084 (2024)
Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC
Externí odkaz:
https://doaj.org/article/3d7b35ff64844380a4515ee7a33416cc
Autor:
Michelle van denBerg, Elleke van derMeij, Annelies M. E. Bos, Marieke C. S. Boshuizen, Domino Determann, Ramon R. J. P. vanEekeren, Christianne A. R. Lok, Eva E. Schaake, Petronella O. Witteveen, Marielle J. Wondergem, Didi D. M. Braat, Catharina C. M. Beerendonk, Rosella P. M. G. Hermens
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1576-1588 (2021)
Abstract Background Decision making regarding future fertility can be very difficult for female cancer patients. To support patients in decision making, fertility preservation decision aids (DAs) are being developed. However, to make a well‐informe
Externí odkaz:
https://doaj.org/article/842fe812d7494a3299762d97e1aa54b9
Autor:
Frederieke H. van derBaan, Josephine J. Koldenhof, Ellen J. deNijs, Michael A. Echteld, Danielle Zweers, Ginette M. Hesselmann, Sigrid C. Vervoort, Jan B. Vos, Everlien deGraaf, Petronella O. Witteveen, Karijn P. Suijkerbuijk, Alexander deGraeff, Saskia C. Teunissen
Publikováno v:
Cancer Medicine, Vol 9, Iss 17, Pp 6111-6121 (2020)
ABSTRACT Background The Utrecht Symptom Diary (USD) is a Dutch and adapted version of the Edmonton Symptom Assessment System, a patient‐reported outcome measurement (PROM) tool to asses and monitor symptoms in cancer patients. This study analyses t
Externí odkaz:
https://doaj.org/article/a1c2eab6eeac49caae9f072272256119
Autor:
Geertruid J. Brink, Jolijn W. Groeneweg, Lotty Hooft, Ronald P. Zweemer, Petronella O. Witteveen
Publikováno v:
Cancers, Vol 14, Iss 12, p 2998 (2022)
For adult granulosa cell tumors (aGCTs), the preferred treatment modality is surgery. Chemotherapy and anti-hormonal therapy are also frequently used in patients with recurrent aGCT. We aimed to review the existing literature on the response to chemo
Externí odkaz:
https://doaj.org/article/e0d30af8b30e407d9a6ca2769753b37b
Autor:
Chris J. de Witte, Joachim Kutzera, Arne van Hoeck, Luan Nguyen, Ingrid A. Boere, Mathilde Jalving, Petronella B. Ottevanger, Christa van Schaik-van de Mheen, Marion Stevense, Wigard P. Kloosterman, Ronald P. Zweemer, Edwin Cuppen, Petronella O. Witteveen
Publikováno v:
Cancers, Vol 14, Iss 6, p 1511 (2022)
The majority of patients with ovarian cancer ultimately develop recurrent chemotherapy-resistant disease. Treatment stratification is mainly based on histological subtype and stage, prior response to platinum-based chemotherapy, and time to recurrent
Externí odkaz:
https://doaj.org/article/9ff70052c2ff4029ab872a302aec9dc5
Autor:
Petronella O. Witteveen, Koen J.C. van der Mijn, Maartje Los, Roelien H. Kronemeijer, Gerard Groenewegen, Emile E. Voest
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 11, Pp 941-945 (2010)
BACKGROUND: Ovarian cancer overexpresses ET-1, and in vitro studies have shown that ET-1 confers resistance to anthracycline-containing chemotherapy. Atrasentan has been developed as an oral selective endothelin-A receptor antagonist. The objective o
Externí odkaz:
https://doaj.org/article/0e99141e46aa431baa1d5af628793457
Autor:
Marlies H.G. Langenberg, Petronella O. Witteveen, Nienke A.G. Lankheet, Jeanine M.L. Roodhart, Hilde Rosing, Ingeborg J.G.M. van den Heuvel, Jos H. Beijnen, Emile E. Voest
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 2, Pp 206-213 (2010)
Introduction. PTK/ZK is a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor receptor, colony-stimulating factor 1 receptor, and cytokine stem cell factor receptor. Cetuximab is a
Externí odkaz:
https://doaj.org/article/6bd3aeff9978448bbf0b19c7a58420cc
Autor:
Josephine J. Koldenhof, Frederieke H. van der Baan, Elisabeth G. Verberne, Annemarleen M. Kamphuis, Rik J. Verheijden, Erwin H. Tonk, Anne S. van Lindert, Janneke van der Stap, Saskia C. Teunissen, Petronella O. Witteveen, Karjin P. Suijkerbuijk
Publikováno v:
Journal of Pain and Symptom Management. 63:997-1005
While praised for inducing durable anti-tumour responses, immune checkpoint inhibitors (ICI) also cause immune-related adverse events (irAEs) that can vary in severity and affect health-related quality of life (HRQL).This study was performed to provi
Autor:
Razelle Kurzrock, Shannon R. Morris, Thomas A. Lampkin, Deborah A. Smith, Laurel Adams, Michael Durante, Joseph F. Kleha, Neeraj Agarwal, Emily Bergsland, E. Claire Dees, Theresa L. Werner, Petronella O. Witteveen, Jennifer Specht, Ruud van der Noll, Jan H.M. Schellens, David Hong, Rahul Aggarwal, Pamela Munster
Purpose: GSK2126458 (GSK458) is a potent inhibitor of PI3K (α, β, γ, and δ), with preclinical studies demonstrating broad antitumor activity. We performed a first-in-human phase I study in patients with advanced solid tumors.Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b58210558b93cf8d4ce8c9aff837b458
https://doi.org/10.1158/1078-0432.c.6524799
https://doi.org/10.1158/1078-0432.c.6524799
Autor:
Razelle Kurzrock, Shannon R. Morris, Thomas A. Lampkin, Deborah A. Smith, Laurel Adams, Michael Durante, Joseph F. Kleha, Neeraj Agarwal, Emily Bergsland, E. Claire Dees, Theresa L. Werner, Petronella O. Witteveen, Jennifer Specht, Ruud van der Noll, Jan H.M. Schellens, David Hong, Rahul Aggarwal, Pamela Munster
Supplementary Table 1. Pharmacokinetic Parameters on Day 1 Following Once daily and Twice Daily Administration of GSK458 Supplementary Table 2. Best Objective Tumor Response by Dose Level (supplementary)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31cc3113a08b14c37c80c2acf0e81ea6
https://doi.org/10.1158/1078-0432.22461510
https://doi.org/10.1158/1078-0432.22461510